HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that it has closed on the Company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals Inc. (Nasdaq: ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company with an ...

Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT OR SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-36612 Lifeward Ltd. (Exact name of registrant as specified in charter) | Israel | Not applicable | | --- | --- | | (State or othe ...

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $22 million, a decrease of approximately 14% from $25.7 million in 2024 [17] - Gross profit increased to $8.4 million or 38.2% of revenue compared to $8.2 million or 32% of revenue in 2024 [19] - Operating expenses declined by 25% to $28.1 million in 2025 compared to $37.6 million in 2024 [20] - Net loss narrowed by 31% to $19.9 million in 2025 compared to $28.9 million in 2024 [22] Business Line Data and Key Metrics Changes - Revenue from ReWalk Personal Exoskeleton was relatively flat at $8.5 million in 2025 compared to $8.9 million in 2024, with units sold increasing by 22% year-over-year [17] - Revenue from MyoCycle FES bike declined by 50% to $600,000, reflecting a strategic focus on core products [18] - Revenue from AlterG products and services was $12.9 million, an 18% decline from 2024, primarily due to lower international sales [18] Market Data and Key Metrics Changes - Reimbursement coverage for ReWalk expanded to include three largest Medicare Advantage insurers in the U.S., covering over 16 million lives [13] - International distribution efforts accelerated following the receipt of CE mark, with Germany as the primary test market [13] Company Strategy and Development Direction - The company is executing a strategy to build a diversified biomedical innovation company with multiple technology platforms [3] - A strategic transaction with Oramed is expected to strengthen the financial foundation and expand strategic scope [4] - Focus on cash flow positive operations while investing in innovations that will define the future of the company [3][25] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about growth in the core med tech business and improvements in operating expenses [15] - The company is focused on building a strong payer engagement capability to expand patient access and accelerate adoption of technologies [11] Other Important Information - The company plans to increase investment in R&D as new products advance to market, including the upper body exoskeleton [21] - A $3 million loan agreement with Oramed was entered into for additional capital support [23] Q&A Session Questions and Answers Question: How does the Oramed POD technology align with the company's current infrastructure? - Management indicated that the integration of Oramed's technology would drive synergies across med tech and biotech, enhancing the company's decentralized approach to commercialization [27][28] Question: What is the timeline for the upper extremity robotic assistance product? - Management stated that the product could be a 510(k) exempt product, with a timeline of 18-24 months for commercialization [32][33] Question: How should investors view the company's diversification into biotech? - Management emphasized that a diversified portfolio in med tech and biotech is beneficial, providing multiple opportunities for product commercialization [42][43]

Lifeward (NasdaqCM:LFWD) Q4 2025 Earnings call March 18, 2026 08:30 AM ET Company ParticipantsAlmog Adar - CFOMark Grant - President and CEOConference Call ParticipantsSwayampakula Ramakanth - Managing Director and Senior Equity Research AnalystYale Jen - Managing Director and Senior Biotechnology AnalystOperatorGood day, and welcome to the Lifeward Inc fourth quarter 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialis ...

Financial Data and Key Metrics Changes - Revenue for the year ended December 31, 2025, was $22 million, a decrease of approximately 14% from $25.7 million in 2024 [18] - Gross profit increased to $8.4 million or 38.2% of revenue compared to $8.2 million or 32% of revenue in 2024 [20] - Operating loss narrowed by 33% to $19.7 million in 2025 compared to $29.3 million in 2024 [22] - Net loss narrowed by 31% to $19.9 million in 2025 compared to $28.9 million in 2024 [22] - Operating cash usage reduced by 23% to $16.8 million in 2025 compared to $21.7 million in 2024 [23] Business Line Data and Key Metrics Changes - Revenue from ReWalk Personal Exoskeleton was relatively flat at $8.5 million in 2025 compared to $8.9 million in 2024, with units sold increasing by 22% year-over-year [18] - Revenue from MyoCycle FES bike declined by 50% to $600,000, reflecting a strategic focus on core products [19] - Revenue from AlterG products and services was $12.9 million, a decline of 18% from 2024, primarily due to lower international sales [19] Market Data and Key Metrics Changes - ReWalk achieved reimbursement coverage with three largest Medicare Advantage insurers in the U.S., representing over 16 million covered lives [13] - International distribution for ReWalk expanded, with Germany as the primary test market [13] Company Strategy and Development Direction - The company is executing a strategy to build a diversified biomedical innovation company with multiple technology platforms [3] - A strategic transaction with Oramed is expected to strengthen the financial foundation and support growth initiatives [4] - The acquisition of technology from Skelable aims to enhance the upper extremity rehabilitation market [6][9] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about growth in the core med tech business and improvements in operating expenses driving the company toward positive cash flow [16] - The company is focused on expanding reimbursement coverage and building a stronger payer engagement capability [11] Other Important Information - The company will not provide guidance at this time due to significant transformations and pending transactions [15] - The strategic agreement with Oramed is expected to close soon, providing additional capital support [23] Q&A Session Summary Question: How does the Oramed POD technology align with the company's commercial infrastructure? - Management indicated that the integration of Oramed's technology will drive synergies across med tech and biotech, enhancing the company's decentralized approach to commercialization [27] Question: What is the timeline for the upper extremity robotic assistance product? - Management stated that the product could be 510(k) exempt and expects to complete the necessary studies within 18-24 months [31][32] Question: How does the company plan to address competition in the upper extremity market? - Management acknowledged the presence of competitors but emphasized the unique approach and simplicity of their product [36] Question: Can the company quantify the backlog entering 2026? - Management noted that while the pipeline is growing, specific numbers are not available at this time, but there is a focus on the 22% growth in units year-over-year [51]

Revenue Performance - Lifeward reported a revenue of $5.1 million in Q4 2025, a decrease of approximately 33% from $7.5 million in Q4 2024[11]. - Revenue for the full year 2025 was $22.0 million, down 14% from $25.7 million in 2024[16]. - Lifeward reported revenue of $5,081,000 for Q4 2025, a decrease of 32.6% compared to $7,545,000 in Q4 2024[32]. - Total revenues for Q4 2025 were $5,081 million, a decrease of 32.6% from $7,545 million in Q4 2024[38]. - The company reported a total revenue of $22,034 million for the year ended December 31, 2025, down from $25,663 million in 2024[38]. Profitability and Loss - Lifeward's net loss narrowed by 65% to $5.3 million, or $3.60 per share, in Q4 2025, compared to a net loss of $15.3 million, or $20.82 per share, in Q4 2024[15]. - The company's net loss for Q4 2025 was $5,348,000, compared to a net loss of $15,278,000 in Q4 2024, representing a 65.0% improvement[32]. - GAAP net loss for Q4 2025 was $(5,348) million compared to $(15,278) million in Q4 2024, showing an improvement[38]. - Non-GAAP net loss per share for Q4 2025 was $(2.85), a decrease from $(4.54) in Q4 2024[38]. Operating Expenses - Total operating expenses in Q4 2025 declined by 64% to $6.2 million from $17.1 million in Q4 2024[13]. - Lifeward's total operating expenses for the full year 2025 decreased by 25% to $28.1 million from $37.6 million in 2024[18]. - Total operating expenses for Q4 2025 were $6,206,000, down from $17,072,000 in Q4 2024, indicating a reduction of 63.6%[32]. Cash and Assets - As of December 31, 2025, Lifeward had $2.2 million in unrestricted cash and cash equivalents[21]. - Cash and cash equivalents at the end of Q4 2025 were $2,169,000, down from $6,746,000 at the end of Q4 2024, a decline of 67.7%[34]. - Lifeward's total assets decreased to $22,900,000 as of December 31, 2025, from $30,487,000 in 2024, a decline of 25.0%[34]. - The company experienced a net cash used in operating activities of $16,826,000 for the year ended December 31, 2025, compared to $21,718,000 in 2024, a reduction of 22.6%[36]. Research and Development - Research and development expenses for the year ended December 31, 2025, were $3,249,000, a decrease of 29.8% from $4,625,000 in 2024[32]. - Research and development expenses for Q4 2025 were $843 million, which is 16.6% of revenue, compared to 15.0% in Q4 2024[40]. Strategic Initiatives - The company expects to close a strategic transaction with Oramed, which includes up to $47 million in additional funding, positioning Lifeward towards cash flow positive[4]. - Lifeward's acquisition of powered upper-body exoskeleton technology is expected to be ready for commercial launch within 18 to 24 months[5]. - The company expanded reimbursement coverage for the ReWalk Personal Exoskeleton, providing access to approximately 16 million covered lives in the U.S.[6]. Liabilities - Lifeward's total current liabilities increased to $12,039,000 as of December 31, 2025, from $10,225,000 in 2024, an increase of 17.8%[34]. Financial Guidance - The company did not provide GAAP reconciliation for its non-GAAP financial guidance due to uncertainties in predicting certain expenses[29].

Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval; Lifeward gains new oral protein delivery technology platform Lifeward already executing new strategy through acquisition of powered upper-body exoskeleton technology Lower operating expenses and cash usage reflect improved operational efficiency HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 18, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. ...

Core Insights - Lifeward Ltd. (NASDAQ:LFWD) is a significant entity in the medical technology sector, focusing on improving the lives of individuals with physical limitations. The company is expected to announce its quarterly earnings on March 18, 2026, with a forecasted earnings per share (EPS) of -$0.96 and revenue of approximately $7.87 million [1][5] Financial Metrics - The company has a negative price-to-earnings (P/E) ratio of -0.33, indicating a lack of profitability. This is further supported by a negative earnings yield of -3.05%, which highlights ongoing challenges in achieving profitability [2] - LFWD's price-to-sales ratio stands at 0.46, suggesting that investors are paying $0.46 for every dollar of sales, indicating a relatively low valuation compared to its sales [3][5] - The enterprise value to sales ratio is slightly lower at 0.38, reflecting a lower valuation when considering debt and cash [3] - The enterprise value to operating cash flow ratio is negative at -0.53, indicating difficulties in generating positive cash flow from operations [4] - The company maintains a low debt-to-equity ratio of 0.019, demonstrating minimal reliance on debt [4][5] - LFWD's current ratio of 1.92 suggests a strong capability to cover short-term liabilities with short-term assets [4][5]

Core Insights - Lifeward is positioned as a diversified biomedical innovation company with a clear path to profitability through its strategic partnership with Oramed Pharmaceuticals, integrating Oramed's POD™ oral delivery technology [1][2][3] Financial Aspects - The partnership allows Lifeward access to up to $47 million in capital through various funding mechanisms, including equity and milestone-based funding [3][4] - Lifeward aims to drive profitability from its established medical technology product portfolio while investing in complementary technologies [4][8] Strategic Opportunities - The integration of the POD™ platform provides Lifeward exposure to a significant biotechnology market, particularly in oral delivery of biologic drugs, which could transform treatment for chronic diseases [5][6] - The POD™ technology has been evaluated in clinical programs for diabetes, a market exceeding $80 billion annually, indicating substantial growth potential [6][7] Operational Focus - Oramed will manage and fund the clinical development of the POD™ platform, allowing Lifeward to concentrate on its existing MedTech business while benefiting from the biotechnology platform's potential [7][8] - Lifeward's strategy includes building a diversified biomedical portfolio that balances immediate revenue generation with long-term innovation opportunities [13]

HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) ("Rule"). To regain complia ...